Andra AP fonden Sells 1,400 Shares of Edwards Lifesciences Corporation (EW)
Andra AP fonden trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 12.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,100 shares of the medical research company’s stock after selling 1,400 shares during the period. Andra AP fonden’s holdings in Edwards Lifesciences Corporation were worth $1,104,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences Corporation by 2.0% in the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after acquiring an additional 406,901 shares in the last quarter. BlackRock Inc. boosted its holdings in Edwards Lifesciences Corporation by 0.8% in the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after acquiring an additional 105,819 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences Corporation by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after acquiring an additional 3,277,726 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Edwards Lifesciences Corporation by 13.3% in the second quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock worth $250,581,000 after acquiring an additional 248,293 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Edwards Lifesciences Corporation by 1.6% in the second quarter. American Century Companies Inc. now owns 2,079,309 shares of the medical research company’s stock worth $245,857,000 after acquiring an additional 32,434 shares in the last quarter. 82.17% of the stock is currently owned by institutional investors.
Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at $105.24 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corporation has a 1 year low of $81.12 and a 1 year high of $121.45. The stock has a market capitalization of $21,976.73, a PE ratio of 28.77, a P/E/G ratio of 1.86 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same quarter in the prior year, the business posted $0.68 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. analysts forecast that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.
EW has been the topic of a number of research analyst reports. Bank of America Corporation upped their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. SunTrust Banks, Inc. upped their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a report on Monday, July 17th. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 price target (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a report on Monday, August 28th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences Corporation presently has a consensus rating of “Buy” and a consensus price target of $125.17.
ILLEGAL ACTIVITY WARNING: “Andra AP fonden Sells 1,400 Shares of Edwards Lifesciences Corporation (EW)” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/14/andra-ap-fonden-sells-1400-shares-of-edwards-lifesciences-corporation-ew.html.
In related news, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the completion of the transaction, the director now directly owns 2,622 shares of the company’s stock, valued at $273,081.30. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The disclosure for this sale can be found here. Insiders have sold 139,580 shares of company stock valued at $15,143,994 in the last quarter. 2.13% of the stock is currently owned by company insiders.
Edwards Lifesciences Corporation Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.